In France, HPV vaccination is currently recommended for girls and boys aged 11 to 14, with the possibility of catch-up vaccination up to the age of 19 for both sexes.
Available studies on the Gardasil 9 vaccine show that it is effective in preventing high-grade precancerous lesions of the cervix and genital warts in a population of women and men aged 16 to 26 at the time of vaccination, including individuals who were uninfected or previously infected with HPV prior to vaccination. However, the level of protection is lower compared to that obtained in a population aged 16 to 26 who had never been infected prior to vaccination. Furthermore, the safety profile of the Gardasil 9 vaccine is well established and considered favorable in both adolescents and young adults.
